NovaQuest led the financing round, which drew participation from eight investors across three continents.
"Following on from our successful seed funding round from Gabriel Investments and Equity Gap, Series A is an important milestone in our global growth plans, as we seek to improve health outcomes for animals through earlier disease diagnosis using revolutionary biomarker technology and artificial intelligence. The geographical spread of this investment round reflects the global opportunity for MI:RNA to deploy our platform for better outcomes for pets."
The funding round was backed by the British Design Fund, angel investors, and a US fund to support commercial rollout.
"Cryogenx’s technology solves a growing global need for a rapid, emergency response for heat illness. What is really impressive about the device is how well designed and thought through it is, being easily transported and operated by a single person, with no pre-preparation or specialist storage required. We look forward to working with Matt and the Cryogenx team as they bring this vital technology to market."
The London startup will use the capital to expand its team, develop next-generation products, and demonstrate clinical performance.
"This could be the defining product in personal health monitoring in the coming decade, and an essential tool for patients and clinicians in diagnosing and treating many chronic diseases as well. Renato and Rafael have a compelling user-centric vision to revolutionise chronic disease management and preventative care, and the credibility and knowledge to execute in this vital area."
Balderton Capital and Exor Ventures have led a seed round to help finance clinical trials and expand manufacturing capabilities.
"At SAVA we are tackling preventable illness by building a new operating system for health monitoring. Our microsensor will revolutionise healthcare by making world-leading monitoring technology available to all. With this capital, we can accelerate our goal of creating a new paradigm for healthcare – preventative, personalised and painless."
Maven Capital Partners led the investment round with backing from Dowgate Capital to accelerate commercial growth.
"The funding secured represents a significant milestone in Real World Health's mission to equip NHS organisations with the tools they desperately need to unlock the hidden potential within their data. The tangible results we've achieved with existing clients, including reducing surgery backlog and improving mental health resource allocation, demonstrate the transformative potential of our solutions. This investment fuels our ability to deliver this impact on a wider scale, ultimately contributing to a more efficient, sustainable, and patient-centred NHS."
